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Expedient Synthesis of Core Disaccharide Building Blocks from 
Natural Polysaccharides for Heparan Sulfate Oligosaccharide 
Assembly 
Nitin J. Pawar,+ Lei Wang,+ Takuya Higo, Chandrabali Bhattacharya, Pavan K. Kancharla, Fuming Zhang, 
Kedar Baryal, Chang-Xin Huo, Jian Liu, Robert J. Linhardt, Xuefei Huang, and Linda C. Hsieh-Wilson*
Abstract: The complex sulfation motifs of heparan sulfate 
glycosaminoglycans (HS GAGs) play critical roles in many important 
biological processes. However, an understanding of their specific 
functions has been hampered by an inability to synthesize large 
numbers of diverse, yet defined, HS structures. Here, we describe a 
new approach to access the four core disaccharides required for 
HS/heparin oligosaccharide assembly from natural polysaccharides. 
The use of disaccharides as minimal precursors rather than 
monosaccharides greatly accelerates the synthesis of HS GAGs, 
providing key disaccharide and tetrasaccharide intermediates in 
about half the number of steps compared to traditional strategies. 
Rapid access to such versatile intermediates will enable the 
generation of comprehensive libraries of sulfated oligosaccharides for 
unlocking the ‘sulfation code’ and understanding the roles of specific 
GAG structures in physiology and disease. 
Introduction 
Heparan sulfate (HS) glycosaminoglycans (GAGs) are linear, 
sulfated polysaccharides that mediate a wide range of important 
biological and disease processes, including cell growth and 
proliferation, brain development, immune regulation, viral 
invasion, angiogenesis, and tumor metastasis.[1] The diverse 
activities of GAGs stem largely from their complex sulfation 
patterns, which facilitate the interactions of GAGs with hundreds 
of different proteins.[2] HS chains are composed of repeating  
 
Figure 1. Representative structure found in HS/heparin and core disaccharide 
building blocks. 
disaccharide units of glucosamine (GlcN) joined via a-1,4-
linkages to either D-glucuronic acid (GlcA) or L-iduronic acid 
(IdoA; Figure 1). Sulfation at the N-, 6-O- and 3-O-positions of 
GlcN and the 2-O-position of GlcA or IdoA produces many 
different sulfation patterns that are tissue-specific, age-specific, 
disease-related, and tightly regulated in vivo.[3] Indeed, a simple 
HS tetrasaccharide has the potential to display 1024 different 
sulfation sequences, highlighting the intriguing capacity of GAGs 
for molecular recognition. However, this chemical complexity has 
limited access to well-defined structures and hampered efforts to 
understand the biology of HS GAGs and to develop HS-based 
therapeutics. 
 Synthetic chemistry provides an elegant solution to this 
challenge. A notable example is the heparin-based 
pentasaccharide drug fondaparinux, which is approved for the 
treatment of deep vein thrombosis. The synthesis of various HS 
analogues was critical for identifying a rare 3-O-sulfated 
sequence that regulates antithrombin III activity.[1a] However, 
despite remarkable progress over the past two decades,[4] the 
synthesis of HS oligosaccharides remains a significant challenge. 
Only a small subset of the potential sulfation motifs has been 
generated, resulting in a paucity of structure-function information 
and hindering broad application of the compounds to biology. 
A major roadblock lies in the preparation of suitable HS 
building blocks. The synthesis of selectively protected IdoA- and 
GlcA-containing disaccharides, which are traditionally derived 
from monosaccharide precursors, usually requires 18-29 steps 
each, depending on the complexity of the protecting groups (See 
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Supporting Information, Figure S1, for representative literature 
examples). This is due to a lack of commercial sources for L-
iduronic acid/L-idose, as well as the need for stereoselective 
formation of glycosidic bonds and elaborate protecting group 
strategies to direct regioselective sulfation. Another major 
roadblock is the lack of universal building blocks for the synthesis 
of HS GAGs. Ideally, virtually any sulfation motif could be obtained 
from a small set of building blocks. The lengthy, laborious 
processes required and the absence of universal building blocks 
have fundamentally limited the ability to produce large, 
comprehensive libraries of HS oligosaccharides. To date, sulfated 
libraries of compounds representing all possible sulfation motifs 
have only been attainable in the case of HS disaccharides.[4o] 
Here, we report a novel, expedient approach to synthesize 
the four core disaccharides required for HS/heparin 
oligosaccharide assembly. We show that these key disaccharides 
can be obtained on a large scale from readily available natural 
polysaccharides and efficiently converted into versatile synthetic 
intermediates. Importantly, by employing disaccharides rather 
than monosaccharides as the minimum precursors, this approach 
eliminates half of the challenging glycosidic bond-forming 
reactions and significantly reduces the total number of steps. The 
new methods described herein should greatly streamline the 
synthesis of HS oligosaccharides and accelerate the production 
of diverse collections of HS GAG sequences. 
Results and Discussion 
Naturally occurring heparin is an attractive starting material 
because it is commercially available (~$14/g) and produced on a 
large scale for pharmaceutical use. We envisioned that key IdoA-
containing building blocks for HS/heparin synthesis might be 
obtained through the controlled hydrolysis of heparin. However, 
hydrolysis of heparin under basic conditions results in b-
elimination to form unsaturated uronic acid moieties,[5] while 
nitrous acid-mediated depolymerization of heparin is 
accompanied by deaminative ring contraction of GlcN.[6] 
Fortunately, elegant studies by Davidson and Meyer,[7] as well as 
Lopin and Jacquinet, [8] showed that chondroitin sulfate (CS) could 
be hydrolyzed using aqueous H2SO4 to provide GlcA-N-
acetylgalactosamine (GalNAc) disaccharides. Selective cleavage 
of the GalNAc-GlcA bond was presumably facilitated by 
neighboring group participation from the N-acetyl group of 
GalNAc. 
Encouraged by these reports, we generated N-acetylated 
(N-Ac) heparin by subjecting sodium heparinate (which is >85% 
N-sulfated) to N-desulfation and N-acetylation[9] and then 
explored the ability of various acids (e.g., H2SO4, TFA, CuCl, 
TMSOTf, BF3Et2O, TfOH) to produce intact HS disaccharides. We 
found that N-Ac-heparin was efficiently hydrolyzed to give 
disaccharides as the major product using 1 M TfOH at 100 °C for 
approximately 6 h (Scheme 1 and Figure S2). The crude free 
disaccharide was then esterified using AcCl and MeOH, which 
also resulted in methylation of the anomeric hydroxyl group. 
Hydrolysis of this methyl glycoside and acetylation of the free 
hydroxyls using acetic anhydride, followed by treatment with 
acetic anhydride/pyridine to effect N-acetylation, resulted in 
peracetylated disaccharide 1. 
Unexpectedly, NMR structural analysis revealed that 
cleavage of the glycosidic bond had occurred predominantly at 
the reducing end of IdoA to give the GlcN-IdoA disaccharide. 
Formation of the other disaccharide, IdoA-GlcN, was not 
observed by NMR, although its presence was detected by 
hydrophilic interaction chromatography-Fourier transform mass 
spectrometry (HILIC-FTMS) (Figure S2). These results suggest 
that the N-acetyl group of heparin does not significantly promote 
the reaction. As further confirmation that an N-acetyl group was 
not required, we performed the reaction directly on sodium 
heparinate. We found that sodium heparinate was efficiently 
hydrolyzed using 2 M TfOH at 100 °C (Figure S3). Extensive 
optimization was conducted to maximize scalability and 
reproducibility. Starting from 25 g of natural heparin, the key GlcN-
IdoA disaccharide 1 was routinely obtained via a one-pot, four-
step reaction sequence (single purification step) in 18% overall 
yield (4.4 g) (Scheme 1, Table S1). Importantly, direct access to 
this disaccharide obviates the need to perform the notoriously 
challenging stereoselective 1,2-cis glycosylation reaction[10] to 
generate GlcN-a(1,4)-IdoA linkages. 
  
  
Scheme 1. Synthesis of GlcN-IdoA and GlcA-GlcN Building Blocks from Natural 
Polysaccharides. TfOH = trifluoromethanesulfonic acid, Ac = acetyl, TfN3 = 
trifluoromethanesulfonyl azide, CbzCl = benzyl chloroformate. 
 The amino groups of HS/heparin are known to be acetylated, 
sulfated, or unmodified in vivo. Thus, to expand the versatility of 
the method further, we sought to convert the N-acetamide of 1 to 
other synthetically useful functionalities. Treatment of the amine 
with TfN3, K2CO3 and ZnCl2 after the esterification step, followed 
by anomeric demethylation and peracetylation, resulted in smooth 
conversion to the desired GlcN3-IdoA disaccharide 1b in 20% 
yield over the four steps (Scheme 1). From 25 g of heparin, 4.8 g 
of disaccharide 1b was obtained in the course of 3-4 days (Table 
S1), highlighting the scalability and practicality of the route. 
Alternatively, the use of benzyl chloroformate introduced a N-Cbz 
protecting group in place of the N-acetyl group to give 1c in 8.5% 
yield over the four steps. 
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 We next investigated whether we could obtain GlcA-
containing disaccharides from heparosan, the biosynthetic 
precursor to heparin. Large-scale fermentation procedures have 
been developed for the purification of heparosan (>100 g) from 
Escherichia coli K5.[11] We found that heparosan was efficiently 
hydrolyzed under slightly milder acidic conditions of 1M TfOH at 
100 °C (Scheme 1 and Figure S4). After esterification and 
peracetylation using similar conditions as before, the GlcA-GlcN 
disaccharide 2 was obtained in 16% overall yield (4.9 g) over the 
four steps (single purification step) starting from 19 g of 
heparosan. In contrast to heparin, cleavage of the glycosidic bond 
occurred exclusively at the reducing end of GlcN to afford the 
GlcA-GlcN disaccharide (Figure S4). We also observed that N-
deacetylated heparosan was hydrolyzed very slowly under the 
same conditions, suggesting the importance of the N-acetyl group 
in this case (Figure S5). The interesting differences in the mode 
of glycosidic bond cleavage between heparin and heparosan are 
presumably due to different stereoelectronic effects during 
oxocarbenium ion formation, which are possibly facilitated by the 
conformational flexibility of the IdoA ring. Possible explanations 
are provided in the SI (Figure S6). Independent of the mechanism, 
it is fortuitous that heparin and heparosan undergo distinct 
cleavages to form two of the four disaccharides required for HS 
assembly (Figure 1). 
 We envisaged that the other two disaccharides might be 
readily accessed through epimerization of 1 and 2. Only a few 
methods have been reported on epimerization as a synthetic 
means to access IdoA from GlcA, and all using 
monosaccharides.[12] Base- or metal-catalyzed interconversion of 
IdoA to GlcA in 1 led to poor overall yield due to b-elimination or 
significant disaccharide decomposition (data not shown). Inspired 
by a report by Wong and colleagues,[12a] we subjected the GlcA-  
 
Scheme 2. Epimerization to Form All Four HS Core Disaccharides. NBS = N-
bromosuccinimide, AIBN = 2,2′-Azobis(2-methylpropionitrile). 
containing 2 to a-bromination using NBS in the presence of UV 
light[12a] to produce the C-5 bromo compound 5 in 75% yield. 
Various radical initiators (AIBN, triethylborane), reducing agents 
(tributyltin hydride, triphenyltin hydride), and temperatures (0-
110 °C) were then explored to effect a-dehalogenation. We found 
that treatment of 5 with Et3B and Bu3SnH at 20 °C gave the 
highest amount of epimerized IdoA-GlcN product 4 in 63% yield, 
along with recovery of the valuable GlcA-GlcN epimer 2 in 31% 
yield (Scheme 2 and Table S2). On the other hand, NBS-
mediated bromination of 1 gave an epimeric mixture of the C-5 
bromo compound 6. Subsequent a-dehalogenation of 6 using  
Scheme 3. Differential protection of the GlcN-IdoA building block. TMSSPh = trimethyl(phenylthio)silane, SPh = benzenethiol, DCM = dichloromethane, 
NapCH(OMe)2 = 2-naphthaldehyde dimethyl acetal, Naph = 2-naphthyl, p-TsOH = p-toluenesulfonic acid, TBAI = tetrabutylammonium iodide, BzCl = benzoyl 
chloride, MS = molecular sieves, BnBr = benzyl bromide, DMF = dimethylformamide, LevOH = levulinic acid, EDC = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 
DMAP = 4-(dimethylamino)pyridine, TBDPSCl = tert-butyl(chloro)diphenylsilane, Im = imidazole, Py = pyridine, TFAA = trifluoroacetic anhydride, NIS = N-
iodosuccinimide. FmocCl = 9-fluorenylmethoxycarbonyl chloride, TFA = trifluoroacetic acid, TFAHN = trifluoroacetamide, STol = 4-methylbenzenethiol, All =  allyl.
AcO O
OAc
AcO
N3 O O
MeO2C
AcO
OAc
SPh
O O
O
HO
N3 O O
MeO2C
HO
OH
SPh
Naph
O O
O
HO
N3 O O
MeO2C
BzO
OH
SPh
Naph
O O
O
BnO
N3 O O
MeO2C
BzO
OBn
SPh
Naph
1b
7 8 9
RO O
OTBDPS
BnO
N3 O O
MeO2C
LevO
OBn
SPh
a TMSSPh  
ZnI2
88%
1. NaOMe, MeOH
82%
Bu2SnO
 TBAI, BzCl
91%
 Ag2OBnBr
70%
1. NaOMe, MeOH 1. p-TsOH, MeOH
2. TBDPSCl, Im, DCM
86%
2. NapCH(OMe)2 
    p-TsOH, CH3CN
DCM, DMF
O O
O
BnO
N3 O O
MeO2C
LevO
OBn
SPh
Naph
2. LevOH, EDC
    DMAP, DCM
10 91% 11 BzCl, Py
14
O OO
BnO
O O
MeO2C
BzO
OBn
SPh
Naph
TFAHN
HO O
ONap
BnO
O O
MeO2C
FmocO
OBn
OCH2CO2t-BuTFAHN
10
1. CH2(CH2SH)2
    Et3N, Py, H2O
2. TFAA, Py
TFA, 
Et3SiH, DCM
81%
72%
HOCH2CO2t-Bu, 
NIS, AgOTf, DCM
82%
15
O OO
BnO
O O
MeO2C
BzO
OBn
OCH2CO2t-Bu
Naph
TFAHN
NaOMe, 
MeOH, DCM O OO
BnO
O O
MeO2C
HO
OBn
OCH2CO2t-Bu
Naph
TFAHN
O OO
BnO
O O
MeO2C
FmocO
OBn
OCH2CO2t-Bu
Naph
TFAHN
16
89%
17 18
b
DCM 4 Å MS
toluene, 70 °C
HO O
ONap
AcO
O O
MeO2C
TrocO
OAc
OAll
TFAHN
AcO O
OTBDPS
AcO
N3 O O
MeO2C
FmocO
OAc
STol
19
7 steps from 1b
20
10 steps from 1
c
FmocCl
Py
90%
12: R = H
13: R = Bz95%
2
1:GlcN-IdoA (62%)
OO
OAc
AcO
AcHN OAc
O
MeO2C
AcO
OAc
AcO
Br
AcO O
OAc
AcO
AcHN O O
MeO2C
AcO
OAc
OAc
AcO O
OAc
AcO
AcHN O
OAcOAcO
OAc
CO2Me
OO
OAc
AcO
AcHNOAc
AcO O
MeO2C
AcO
OAc
AcO O
OAc
AcO
AcHN O O
MeO2C
AcO
OAc
OAc
Br
5
6
4: IdoA-GlcN (63%)
3: GlcN-GlcA (33%)
NBS, CCl4 
hυ, reflux
75%
Bu3SnH, Et3B
toluene
94%
2: GlcA-GlcN (31%)
OO
OAc
AcO
AcHNOAc
O
MeO2C
AcO
OAc
AcO
1
NBS, CCl4 
hυ, reflux
80%
Bu3SnH, AIBN
toluene
95%
10.1002/anie.201908805
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Angewandte Chemie International Edition
This article is protected by copyright. All rights reserved.
 RESEARCH ARTICLE          
 
 
 
 
AIBN and Bu3SnH at 110 °C afforded the GlcN-GlcA disaccharide 
3 in 33% yield (Scheme 2 and Table S3). Although only moderate 
conversion to GlcN-GlcA was observed, the GlcN-IdoA building 
block 1 could be recovered in 62% yield and readily recycled to 
produce more GlcN-GlcA building block. Thus, this approach 
provides novel streamlined routes to all four of the core HS 
disaccharide modules (1-4; Figure 1). 
The assembly of HS oligosaccharides with defined sulfation 
sequences requires orthogonally protected disaccharides bearing 
functionalities that can be selectively removed to unmask 
hydroxyl or amino groups for sulfation. We therefore sought to 
synthesize strategically protected building blocks from the core 
disaccharides. Disaccharide 1b was treated with ZnI2 and 
TMSSPh to give the corresponding thioglycoside 7 in 88% yield 
(Scheme 3a). After global deacetylation, the 6-O- and 4-O- 
hydroxyl groups of GlcN were protected with a (2-naphthyl) 
methylene acetal to afford compound 8. Next, we investigated the 
selective 2-O-protection of IdoA, which is particularly challenging 
for trans-di-axial 1,2-diols. Treatment of 8 with dibutyltin oxide and 
benzoyl chloride at 70 °C gave the desired compound 9 as the 
exclusive product. Although dibutyltin oxide has been widely used 
for the regioselective protection of cis-1,2 and di-equatorial trans-
1,2 diols,[13] to our knowledge, this is the first successful 
application of dibutyltin oxide to the regioselective protection of 
the di-axial trans 2-O- or 3-O-positions of IdoA. We found that 9-
fluorenylmethoxycarbonyl (Fmoc), 2,2,2-trichloroethoxycarbonyl 
(Troc), and benzoyl (Bz) groups could be selectively installed at 
the 2-O-position of GlcN-IdoA derivatives, whereas the 
monochloroacetyl (MCA) group could be selectively installed at 
the 3-O-position, highlighting the synthetic utility of this 
transformation (Table S4). Benzylation of the remaining hydroxyl 
groups in 9 using Ag2O and BnBr in 1:1 DCM/DMF gave the 
valuable intermediate 10 in only 9 steps (5 purifications) from 
heparin. For comparison, an analogous disaccharide containing a 
cyclic benzylidene acetal was synthesized by Gardiner and 
coworkers over 17 steps in the shortest route to date (Figure 
S1).[4m,4n] 
Disaccharide 10 is a highly versatile intermediate that can 
be used to synthesize various simple to highly complex HS 
oligosaccharides. For example, regioselective opening of the 
Naph acetal would lead to a 6-O-(2-naphthyl)methyl (Nap) ether 
group and unmask the 4-O hydroxyl group, providing a glycosyl 
acceptor for HS chain elongation. Here, we chose to convert 
disaccharide 10 into the highly differentially protected 
disaccharide donor 13 and acceptor 18 as general building blocks 
for the synthesis of various HS sulfation motifs. These building 
blocks have five O-protecting groups (tert-butyldiphenylsilyl 
(TBDPS), levulinoyl (Lev), Nap, Fmoc and CO2t-Bu) and two N-
protecting groups (N3, N-trifluoroacetyl (TFA)), whose 
orthogonality is well documented.[14, 4b] This overall strategy 
maximizes the number of possible sulfation patterns from each 
disaccharide, enabling the generation of up to 64 different 
sulfation sequences from a single protected tetrasaccharide. 
The required disaccharide donor 13 was synthesized by 
exchanging the 2-OBz group of 10 for a Lev group, removal of the 
Naph acetal, and protection of the resulting primary and 
secondary hydroxyl groups with TBDPS and Bz groups, 
respectively. To generate the disaccharide acceptor 18, the azido 
group of 10 was reduced and the resulting amine protected with 
a TFA group to afford 14 in 81% yield over two steps (Scheme 
3b). Glycosylation of 14 using tert-butyl 2-hydroxyacetate gave 
compound 15 with a versatile linker[15] at the reducing end. 
Chemoselective deprotection of the 2-OBz group in 15, followed 
by Fmoc protection of the resultant secondary alcohol and 
regioselective opening of the Naph acetal, gave the desired 
acceptor 18 in 72% yield. Differentially protected disaccharides 19 
- 20 were also successfully synthesized using similar reaction 
sequences (Scheme 3c, S1 and S2). In the future, orthogonally 
protected GlcN-GlcA disaccharides derived from 3 can be readily 
produced. Overall, strategic protection of the core disaccharides 
1/1b with different sets of protecting groups was accomplished to 
provide key HS/ heparin disaccharide building blocks in only 5-11 
steps.  
With the disaccharides in hand, we sought to generate a 
highly orthogonally protected tetrasaccharide that could serve as 
a ‘universal’ building block for the generation of many sulfation 
sequences. Surprisingly, glycosylation of donor 19 with model 
acceptor 20 gave the undesired  b-anomer, as determined by 
HMQC and NOE analysis (Scheme S3). Although participation of 
the axially oriented 3-OAc moiety of 19 following anomeric 
activation could promote the observed β-selectivity, exchanging 
the 3-OAc with an OBn group did not alter the glycosylation 
selectivity (data not shown). Therefore, we reasoned that the 
Fmoc carbonate group may not provide strong enough 
neighboring group participation to overcome the intrinsic β-
selectivity of the glycosylation reaction, which prompted us to 
examine the 2-OLev ester protected donor 13. Reaction of donor 
13 with acceptor 18 using NIS and AgOTf at room temperature 
delivered tetrasaccharide 21 with exclusively the desired a-  
Scheme 4. A universal tetrasaccharide building block for the generation 
of diverse HS sequences. a) Assembly of the strategically protected 
tetrasaccharide 21. b) Demonstration of the orthogonality of the TBDPS, Nap, 
Lev, Fmoc, and t-Bu protecting groups. DDQ = 2,3-dichloro-5,6-dicyano-p-
benzoquinone. 
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Scheme 5. Regioselective sulfation of the 2-O, 6-O and N positions to give tetrasaccharides bearing asymmetrical, regiodefined sulfation patterns.
stereochemistry (1JC–H = 174.3 Hz) in 60% yield, in addition to 
18% recovery of unreacted acceptor 18 (Scheme 4a). Thus, the 
new methods reported herein have enabled synthesis of the 
uniquely designed, highly orthogonally protected HS 
tetrasaccharide 21, with seven different protecting groups 
(TBDPS, Lev, Nap, Fmoc, CO2t-Bu, N3, and TFA) and 
differentiation of the two nitrogen atoms, in only 21 steps. 
We next demonstrated the orthogonality of the O-protecting 
groups in tetrasaccharide 21. Selective removal of the TBDPS or 
Nap group was achieved using HF.Py or DDQ, respectively, to 
give compounds 22 and 23 (Scheme 4b). Alternatively, the Lev- 
or Fmoc groups could be chemoselectively removed using 
hydrazine acetate or piperidine, respectively, to afford compounds 
24 and 25. To provide a carboxylic acid handle for the potential 
attachment to a solid support, the t-Bu ester at the reducing end 
was selectively hydrolyzed using 3% TFA in DCM to obtain 
compound 26. Thus, each 2-O-, 6-O, or amino group in 21 can be 
selectively unmasked for regioselective sulfation, allowing in 
principle for the production of 64 different sulfation motifs from a 
single, universal tetrasaccharide building block. 
 To demonstrate the versatility of 21, we generated 
tetrasaccharides with regiodefined sulfation patterns. Sulfation of 
free hydroxyl groups in 22 and 25 using sulfur trioxide 
triethylamine complex gave the 6-O- and 2-O-monosulfated 
tetrasaccharides 27 and 28, respectively (Scheme 5). These 
results confirm that all of the protecting groups (TBDPS, Nap, Lev, 
Fmoc, N3 and TFA) remain intact under typical sulfation conditions 
and that our approach can allow for regioselective sulfation of the 
2-O-, 6-O- and N-positions of tetrasaccharide 21. Deprotection of 
the TBDPS group of 28, global ester and trifluoroacetamide 
hydrolysis using LiOH, and acetylation of the resultant primary 
amine provided compound 29. Subsequent hydrogenolysis of the 
benzyl and Nap groups with concomitant reduction of the N3 
group and chemoselective N-sulfation delivered the defined 
sulfated tetrasaccharide 30. On the other hand, treatment of 27 
with thioacetic acid accomplished the one-pot conversion of the 
azide to the acetamide to give compound 31. Global hydrolysis, 
followed by hydrogenolysis and chemoselective N-sulfation as 
before, delivered the desired sulfated compound 32. Thus, 
tetrasaccharide 21 can serve as a versatile intermediate for the 
synthesis of HS GAGs displaying different regiodefined sulfation 
patterns. It is worth noting that structures such as 30 and 32 
bearing distinct O-sulfation and N-sulfation patterns on its two 
disaccharide units are generally more tedious to prepare 
chemically and are inaccessible using current chemoenzymatic 
methods. 
Conclusion 
In summary, we have developed novel, concise and scalable 
routes to obtain key HS/heparin disaccharide building blocks from 
natural heparin and heparosan polysaccharides. We demonstrate 
that the use of naturally-derived disaccharides as minimal 
synthetic precursors accelerates the synthesis of HS GAGs,   
providing general and versatile disaccharide and tetrasaccharide 
building blocks for the assembly of HS/heparin oligosaccharides 
in about half the number of steps compared to traditional 
approaches starting from monosaccharides. Future studies will 
focus on obtaining large numbers of diverse, sulfated 
oligosaccharides through the exploration of solid-phase synthesis 
methodologies, library encoding strategies, and automation.[14a, 16] 
Rapid access to key, universal HS building blocks promises to 
significantly expand the scope of HS synthesis, enabling the 
future generation of large libraries of compounds for deciphering 
the ‘sulfation code’ and developing new GAG-based therapies. 
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Full experimental details and compound characterizations are 
provided in the Supplementary Information, including supporting 
figures, tables, experimental procedures, characterization data, 
and NMR spectra. 
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